Skip to content

Oral Bedtime Melatonin in Critically Ill Patients

Oral Bedtime Melatonin in Critically Ill Patients

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06156059
Acronym
Mel-ICU
Enrollment
160
Registered
2023-12-05
Start date
2025-02-01
Completion date
2026-04-01
Last updated
2024-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest, Septic Shock, Stroke Hemorrhagic, Strokes Thrombotic

Brief summary

Oxidative stress is one of the main mechanisms causing harm in severe infection with septic shock, ischemia-reperfusion injury in resuscitated cardiac arrest and ischemic and hemorrhagic stroke. Melatonin is a potent scavenger of the mediators of oxidative stress, oxygen and nitrogen-reactive species, which directly injure cell structures like walls and DNA and thus cause organ dysfunction. In a previous study we have observed that high-dose oral bedtime melatonin (OBM) is associated with improved organ function in severe Covid-19 patients

Detailed description

This is a double-blind randomized, adaptive trial in the 4 indications mentioned above giving 100 mg of OBM or placebo. Interim analyses with pre-specified stopping rules will be performed in each sub-study for specific outcome variables collected at scheduled timelines. Comparative organ dysfunction score (Sequential Organ Failure Evaluation-SOFA) will be done at baseline, 7, 14, and 30 days and mortality evaluated at 30 and 90 days. For the 3 study groups enrolling stroke and resuscitated cardiac arrest patients, the modified Rankin score and the CVC (Glasgow) at 30 and 90 days will be compared.

Interventions

100 mg oral suspension or capsule given at bedtime

DRUGPlacebo suspension or capsule

Indistinguishable suspension or capsule

Sponsors

Universidad Complutense de Madrid
CollaboratorOTHER
Hospital San Carlos, Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Indistinguishable oral suspension or capsule

Intervention model description

double blind randomized

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* ICU stay \>5 days

Exclusion criteria

* ominous prognosis

Design outcomes

Primary

MeasureTime frameDescription
Mortality at 90 daysInclusion to 90 daysAll-cause mortality

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026